Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	49.85M
Revenue (ttm)	66.14M
Net Income (ttm)	-18.28M
Shares Out	69.82M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	1.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	905,412
Average Volume	128,945
Open	0.7200
Previous Close	0.7140
Day's Range	0.6600 - 0.7200
52-Week Range	0.6000 - 2.2500
Beta	-0.07
RSI	35.64
Earnings Date	May 9, 2025

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 38
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT

Financial Performance

In 2024, Sprint Bioscience AB's revenue was 66.14 million, an increase of 27.97% compared to the previous year's 51.69 million. Losses were -18.28 million, 4072.8% more than in 2023.